Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steiner, M.
Right arrow Articles by Theisen, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steiner, M.
Right arrow Articles by Theisen, J
American Journal of Health-System Pharmacy, Vol 60, Issue 10, 1023-1028
Copyright © 2003 by American Society of Health-System Pharmacists

Articles

Patient outcomes after therapeutic interchange of dolasetron for granisetron

MA Steiner, RZ Yorgason, LC Vermeulen, and J Theisen


The impact of using therapeutic interchange (TI) of dolasetron for granisetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) was evaluated. An outcomes evaluation was conducted in two cohorts of adult outpatients who had not previously received chemotherapy. Before the interchange, 20 patients were enrolled in a granisetron cohort, and after the interchange to dolasetron, 42 patients were matched to the initial cohort. Evaluations using the modified Functional Life Index--Emesis (MFLIE) compared changes in functional status before and after treatment. Nausea and vomiting frequency, satisfaction with antiemetics, reported adverse effects, changes in antiemetic therapy, and the use of antiemetics postchemotherapy were also evaluated. Success, defined as no vomiting and less than a 2.5-unit change in MFLIE score, was demonstrated in 45% of granisetron patients and 40% of dolasetron patients (p = 0.461). While functional status declined in both groups in response to chemotherapy, the changes in MFLIE scores did not differ between agents (-16.8 +/- 20.16 versus -19.39 +/- 26.36 in granisetron and dolasetron patients, respectively) (p = 0.650). Patients were equally satisfied with their prescribed antiemetic therapy, although less than half of patients achieved antiemetic success in the 72-hour study period. Self-reported adverse events attributed to serotonin type 3-receptor antagonist use were minimal and not significantly different between groups. The TI did not negatively affect patient outcomes and produced savings of $143,534 in the first year of the program. TI of dolasetron for granisetron for CINV did not affect functional status, nausea control, or patient satisfaction with antiemetic therapy.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems
Am. J. Health Syst. Pharm., July 15, 2008; 65(14): 1368 - 1384.
[Full Text] [PDF]

Home page
 Integr Cancer TherHome page
S. Price, G. Lewith, and K. Thomas
Acupuncture care for breast cancer patients during chemotherapy: a feasibility study.
Integr Cancer Ther, December 1, 2006; 5(4): 308 - 314.
[Abstract] [PDF]

Home page
 Anesth. Analg.Home page
P. K. Janicki, H. G. Schuler, T. M. Jarzembowski, and M. Rossi II
Prevention of Postoperative Nausea and Vomiting with Granisetron and Dolasetron in Relation to CYP2D6 Genotype.
Anesth. Analg., April 1, 2006; 102(4): 1127 - 1133.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society of Health-System Pharmacists.